Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150031/S102

Vercise Deep Brain Stimulation (DBS) Systems

Boston Scientific Corp · Decision date Oct 30, 2026

MEDTECHLEDGER EXPLANATIONP150031/S102

What did the FDA decide?

The FDA recorded a decision dated 2026-10-30 on supplement P150031/S102 for the Vercise Deep Brain Stimulation (DBS) Systems, submitted by Boston Scientific Corp. The supplement was filed as a 30-Day Notice under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier, and the recorded decision is OK30. The device category is an implanted electrical stimulator for parkinsonian symptoms, with product code NHL and Neurology as the specialty.

The recorded scope is narrow: approval to increase the mold temperature parameter used in the injection molding process for manufacturing the seal stack component. This is a manufacturing process parameter change for one component, not a new approval of the Vercise DBS system as a whole, and the source does not describe clinical data, sterilization effects or the seal stack's role in the finished device. The source also does not state what OK30 denotes or the basis for the decision, so those points remain unknown.

FDA approval order statement

approval to increase the mold temperature parameter used in the injection molding process for manufacturing the seal stack component
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Oct 30, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150031/S102
Regulatory pathway
PMA supplement
Product code
NHL
Decision code
OK30
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implanted, for parkinsonian symptoms.

Product code
NHL
FDA device class
3

For the original device and its historical approval scope, see PMA P150031. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150031 · Original PMA

    VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM

  2. P150031/S084 · Related supplement

    VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEM

  3. P150031/S098 · Related supplement

    Vercise Genus DBS Systems; Vercise Gevia DBS Systems

  4. P150031/S102 received

    Application receipt date recorded by FDA.

  5. P150031/S102 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P150031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150031

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalDec 8, 2017FDA
Boston Scientific CorpPMA supplementSep 13, 2026FDA
Boston Scientific CorpPMA supplementSep 22, 2026FDA
Boston Scientific CorpPMA supplementOct 15, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
25155 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records